ZA200605841B - Prolinylarylacetamides - Google Patents

Prolinylarylacetamides Download PDF

Info

Publication number
ZA200605841B
ZA200605841B ZA200605841A ZA200605841A ZA200605841B ZA 200605841 B ZA200605841 B ZA 200605841B ZA 200605841 A ZA200605841 A ZA 200605841A ZA 200605841 A ZA200605841 A ZA 200605841A ZA 200605841 B ZA200605841 B ZA 200605841B
Authority
ZA
South Africa
Prior art keywords
denotes
hydroxypyrrolidine
chlorophenyl
solvates
phenyl
Prior art date
Application number
ZA200605841A
Other languages
English (en)
Inventor
Mederski Werner
Dorsch Dieter
Gleitz Johannes
Tsaklakidis Christos
Cezanne Bertram
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA200605841B publication Critical patent/ZA200605841B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
ZA200605841A 2003-12-16 2006-07-14 Prolinylarylacetamides ZA200605841B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10358814A DE10358814A1 (de) 2003-12-16 2003-12-16 Prolinylarylacetamide

Publications (1)

Publication Number Publication Date
ZA200605841B true ZA200605841B (en) 2007-10-31

Family

ID=34683363

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200605841A ZA200605841B (en) 2003-12-16 2006-07-14 Prolinylarylacetamides

Country Status (16)

Country Link
US (1) US7732481B2 (cg-RX-API-DMAC7.html)
EP (1) EP1697318B1 (cg-RX-API-DMAC7.html)
JP (1) JP4800969B2 (cg-RX-API-DMAC7.html)
KR (1) KR20060113729A (cg-RX-API-DMAC7.html)
CN (1) CN1894210A (cg-RX-API-DMAC7.html)
AR (1) AR046765A1 (cg-RX-API-DMAC7.html)
AT (1) ATE406350T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004299197B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0417630A (cg-RX-API-DMAC7.html)
CA (1) CA2549589A1 (cg-RX-API-DMAC7.html)
DE (2) DE10358814A1 (cg-RX-API-DMAC7.html)
ES (1) ES2310772T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA06006740A (cg-RX-API-DMAC7.html)
RU (1) RU2006125509A (cg-RX-API-DMAC7.html)
WO (1) WO2005058817A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200605841B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1818330A1 (de) * 2006-02-14 2007-08-15 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Prolinamide, deren Herstellung und deren Verwendung als Arzneimittel
PL2051975T3 (pl) * 2006-05-16 2013-01-31 Boehringer Ingelheim Int Podstawione prolinamidy, ich wytwarzanie oraz ich zastosowanie jako środków leczniczych
BRPI0813230A2 (pt) * 2007-06-28 2014-12-23 Novartis Ag Moduladores de calicreína 7
WO2011027888A1 (ja) * 2009-09-07 2011-03-10 大日本住友製薬株式会社 ジアミド-フェニル誘導体、またはその薬学的に許容される塩
CN109761957B (zh) * 2019-01-18 2020-05-19 西安交通大学 一种含有羟脯氨酸的化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
PL377633A1 (pl) 2003-04-03 2006-02-06 Merck Patent Gmbh Związki karbonylowe
WO2004087696A1 (de) * 2003-04-03 2004-10-14 Merck Patent Gmbh Pirazolidin-1,2-dicarbonsaüre-1-((phenyl)-amid)-2-((phenyl)-amid) derivate als koagulationsfaktor xa inhibitoren zur behandlung von thrombosen
DE102004014945A1 (de) * 2004-03-26 2005-10-13 Merck Patent Gmbh Prolinylderivate

Also Published As

Publication number Publication date
KR20060113729A (ko) 2006-11-02
WO2005058817A1 (de) 2005-06-30
AR046765A1 (es) 2005-12-21
ATE406350T1 (de) 2008-09-15
US7732481B2 (en) 2010-06-08
US20070185189A1 (en) 2007-08-09
AU2004299197A1 (en) 2005-06-30
DE502004007959D1 (de) 2008-10-09
JP2007513988A (ja) 2007-05-31
MXPA06006740A (es) 2006-08-18
RU2006125509A (ru) 2008-01-27
BRPI0417630A (pt) 2007-03-27
CN1894210A (zh) 2007-01-10
AU2004299197B2 (en) 2010-08-05
DE10358814A1 (de) 2005-07-21
CA2549589A1 (en) 2005-06-30
ES2310772T3 (es) 2009-01-16
EP1697318B1 (de) 2008-08-27
JP4800969B2 (ja) 2011-10-26
EP1697318A1 (de) 2006-09-06

Similar Documents

Publication Publication Date Title
ZA200305455B (en) Carboxylic acid amide derivatives and their use in the treatment of thromboembolic diseases and tumours.
US20040087582A1 (en) Phenyl derivatives
ZA200508891B (en) Pyrazolidine-1,2-dicarboxyldiphenylamide derivatives as coagulation factor Xa inhibitors for the treatment of thromboses
NZ543366A (en) Carbonyl compounds
ZA200308028B (en) Phenyl derivatives 3.
ZA200404147B (en) Pyrrolidine-2-ones as factor Xa inhibitors.
ZA200302252B (en) Aza-amino acid derivatives (Factor Xa-inhibitors 15).
ZA200308669B (en) Oxalic acid derivatives.
MXPA02008207A (es) Derivados de aminosulfonilbifenilo.
ZA200605839B (en) Carboxamide derivatives
ZA200404549B (en) Drivatives of phenoxy-N-[4-(1,1-dioxoisothiazolidin-2-yl)phenyl]-valeramide and other compounds as inhibitors of coagulation factor Xa for treatment of thromboembolic diseases and tumuors.
ZA200608875B (en) Prolinyl derivatives for treating thrombosis
US20050176760A1 (en) N-'4-(2-imino-pyrrolidin-1-yl)phenyl!-acetamide and corresponding piperidine derivatives as factor xa inhibitors for the treatment of thrombo-embolic diseases
ZA200308060B (en) Biurethane derivatives.
JP4409941B2 (ja) 第Xa因子阻害剤としてのフェニル誘導体
US20030176465A1 (en) Cyclic amino acid derivatives
ZA200506730B (en) Carboxamide derivatives and their use as factor XA inhibitors
US20010049449A1 (en) Aromatic sulfonyl alpha-cycloamino hydroxamates and their use as MMP inhibitors
ZA200407903B (en) Semicarbazide derivatives and their use as antithrombotics.
CA2628963A1 (en) Benzene derivative or salt thereof
RU2006125509A (ru) Полиниларилацетамиды
ZA200607219B (en) Urea derivatives
US20040092517A1 (en) Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours
ZA200600155B (en) Aroryl semicarbazide derivatives against thromboembolic diseases
ZA200507818B (en) Ethynyl derivatives serving as factor Xa inhibitors